lifastuzumab vedotin

Home
Ligands
lifastuzumab vedotin

GtoPdb Ligand ID: 8405

Synonyms: DNIB0600A | RG-7599 | RG7599

Comment: Lifastuzumab vedotin is an antibody drug conjugate containing an anti-SLC34A2 (sodium phosphate 2 transporter) monoclonal antibody linked to the toxin monomethyl auristatin E (MMAE, aka vedotin; PubChem CID 11542188).
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record. Peptide sequence match identifies US8535675 as the covering patent [2], and also identifies the target antigen denoted as TAT211 in this patent as the sodium phosphate transporter.

Summary
Biological activity
Clinical data
References

No information available.

No information available.

Summary of Clinical Use
Lifastuzumab vedotin is being evaluated in Phase 2 clinical trials as a potential treatment for platinum-resistant ovarian cancer and additionally non-small cell lung cancer (NSCLC) in Phase 1.

Summary of Clinical Use

Lifastuzumab vedotin is being evaluated in Phase 2 clinical trials as a potential treatment for platinum-resistant ovarian cancer and additionally non-small cell lung cancer (NSCLC) in Phase 1.